Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.

Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.


A Miami man has pleaded guilty in federal court to distributing adulterated HIV drugs dispensed to U.S. patients.

Miami Herald | Tribune News Service | Getty Images

A Miami man pleaded guilty to distributing as much as $25 million worth of misbranded and adulterated HIV drugs that were dispensed by pharmacies across the U.S. to unsuspecting patients, federal prosecutors said.

Armando Herrera, 43, faces a maximum possible sentence of five years in prison for the crime.

Herrera pleaded guilty in U.S. District Court in Miami on Monday to one count of conspiracy to introduce adulterated and misbranded drugs in the U.S. market, court filings show.

A medication is adulterated if a substance has been substituted for the drug in whole or in part.

Herrera and his co-conspirators set up companies in Texas, California and Washington state that acquired large quantities of misbranded and adulterated HIV medication from legal channels, falsified the pills’ packaging and sold them at a steep discount to wholesalers that later sold them to pharmacies, court documents say.

Prosecutors said the wholesalers were involved in the criminal scheme, but the pharmacies were unaware that the drugs were altered or misbranded.

The adulterated and misbranded drugs included Truvada, Biktarvy and other unnamed medications.

Truvada is prescribed to prevent HIV infection in people who are at risk of contracting the virus. The medication is also used in combination with other drugs to treat infection.

Biktarvy is prescribed to treat HIV infection. Truvada and Biktarvy are manufactured by Gilead Sciences.

Herrera and his co-conspirators received between $16.7 million and $25 million in payment from two wholesalers, according to court filings.

The filings did not say how Herrera and his co-conspirators acquired the drugs.

Medications are often siphoned off the legal market by purchasing them from individual patients who were prescribed the drugs.

Herrera is scheduled to be sentenced Dec. 21. His lawyer did not immediately respond to CNBC’s request for comment.



Source

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Health

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.  The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]

Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More
Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’
Health

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

U.S. President Donald Trump speaks next to Defense Secretary Pete Hegseth during a cabinet meeting at the White House in Washington, D.C., U.S., July 8, 2025. Kevin Lamarque | Reuters President Donald Trump on Tuesday threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”  “They’re going to be tariffs […]

Read More